Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option and License Agreement to Advance Vectorized Antibodies for the treament of Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

September 18, 2025 0

VectorY Therapeutics in the NEWS September 18, 2025 – VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and Shape Therapeutics Inc., a biotechnology company harnessing AI and RNA technologies to engineer next-generation genetic medicines, announced Today that they have entered into an option and license agreement. The Agreement The agreement grants VectorY …

Helping Your Pets to be Healthy and Live Longer

Praxis Precision Medicines Radiant Study with Vormatrigine

ARS Pharmaceuticals Announces FDA Approval of neffy® for Type I...

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its...

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the...

The United States FDA Approved Astellas’ product VYLOY in Combination...

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced...

Novo Nordisk Launches New Initiative To Prevent Childhood Obesity In...

The FDA Approved IntraBio Product AQNEURSA As the only treatment...

Jeune Aesthetics: Reversing the Biology of Aging Skin to Meet...

Galderma Receives U.S. FDA Approval for Nemluvio® for Adult Patients...

SCG Cell Therapy: FDA Approved IND Application of Product SCG142...

Mitsubishi Tanabe Pharma America Announced the Presentations of its ND0612...

AstraZeneca: The U.S. FDA Approved IMFINZI in Combination with Carboplatin...

Regeneron: Improved Hearing to Normal Levels in a Child with...

INmune Bio Inc. Update on Two Alzheimer Disease Patients Who...

Cerevel Therapeutics Announces Positive Results for Tavapadon in Phase 3...

Italfarmaco Received FDA Approval for Duvyzat™ for the Treatment of...

Abbott Laboratories Launches a New PROTALITY™ Brand to Maintain the...

Impacting News

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

September 25, 2025 0

uniQure in the NEWS On September 24, 2025, uniQure N.V. (QURE) - a gene therapy company advancing transformative …

Important: Two Press Releases in the Past 2 Days from Grail & Intellia Therapeutics

September 24, 2025 0

Important News from Grail Inc. and Intellia Therapeutics Grail Inc Press Realease GRAL to Present New …

Jazz Pharmaceuticals to Treat H3 K27M-Mutant Diffuse Midline Glioma

September 16, 2025 0

Jazz Pharmaceuticals On September 9, 2025, Jazz Pharmaceuticals plc (JAZZ) announced that Modeyso™ (dordaviprone) is recommended by …

Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes. The Stock’s Price is Soaring.

September 9, 2025 0

Alnylam Pharmaceuticals Press Release Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that …

Regeneron Pharmaceuticals Libtayo® Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-Small Cell Lung Cancer

September 9, 2025 0

Regeneron Pharmaceuticals Announcement Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a …

FDA New Approvals of COVID-19 Vaccines

August 28, 2025 0

Approved COVID-19 Vaccines As of late August 2025, the U.S. Food and Drug Administration (FDA) has …

Trick or Trade

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.

September 18, 2025 0

Lexicon Pharmaceuticals in the NEWS Yesterday, September 17, 2025, Lexicon Pharmaceuticals (LXRX) announced the presentation of …

The FDA is Taking Concrete Steps to Reduce Opioid Misuse, Addiction and Overdose Strengthening Guidance on Their Appropriate Use

September 11, 2025 0

Xenon Pharmaceuticals A Company Treating Chronic Pain Xenon Pharmaceuticals (XENE) - a neuroscience-focused biopharmaceutical company dedicated …

Alnylam’s Presentation In Early September

August 28, 2025 0

Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The …

Klotho Neurosciences to Expand Development Programs Beyond Neurology

July 28, 2025 0

Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity …

Question & Answer About Kiniksa Pharmaceuticals

July 17, 2025 0

Q & A: Kiniksa Pharmaceuticals Q: Do you have any recent news from Kiniksa Pharmaceuticals? A: …

Why We Believe That BioNTech Will Have A Great Future

June 18, 2025 0

Biotechnology and biopharmaceutical firms were doing great until the day the COVID-19 pandemic changed the lives …

Today’s Highlights

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

October 9, 2025 0

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics (AKRO) announced that it entered into …

U.S. FDA Lifts Clinical Hold on NUZ-001, Neurizon® Lead Investigational Therapy for ALS

October 6, 2025 0

Neurizon Therapeutics in the NEWS Today October 6, 2025, from Melbourne, Australia: Neurizon Therapeutics Limited (ASX: …

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025 0

Genmab in the NEWS Denmark; UTRECHT, The Netherlands; Today, Genmab (GMAB) and Merus (MRUS) announced that …

Eli Lilly’s Oral GLP-1, Orforglipron, is Superior to Oral Semaglutide in Head-to-Head Trial

September 17, 2025 0

Eli Lilly Eli Lilly and Company (LLY) today September 17, announced positive topline results from ACHIEVE-3, Phase …

Alkermes: Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

September 8, 2025 0

Alkermes in the NEWS Today, Alkermes Inc., (ALKS) announced detailed positive results from the Vibrance-1 phase …

Ionis Pharmaceuticals Product Olezarsen Significantly Reduces Triglycerides and Acute Pancreatitis Events in Landmark Pivotal Studies for People with Severe Hypertriglyceridemia

September 2, 2025 0

Ionis Pharmaceuticals in the NEWS Today, Sep. 2, 2025, Ionis Pharmaceuticals (IONS) announced positive topline results …

Latest Articlesddd

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

October 9, 2025 0

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics (AKRO) announced that it entered into …

U.S. FDA Lifts Clinical Hold on NUZ-001, Neurizon® Lead Investigational Therapy for ALS

October 6, 2025 0

Neurizon Therapeutics in the NEWS Today October 6, 2025, from Melbourne, Australia: Neurizon Therapeutics Limited (ASX: …

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025 0

Genmab in the NEWS Denmark; UTRECHT, The Netherlands; Today, Genmab (GMAB) and Merus (MRUS) announced that …

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

September 25, 2025 0

uniQure in the NEWS On September 24, 2025, uniQure N.V. (QURE) - a gene therapy company advancing transformative …

Important: Two Press Releases in the Past 2 Days from Grail & Intellia Therapeutics

September 24, 2025 0

Important News from Grail Inc. and Intellia Therapeutics Grail Inc Press Realease GRAL to Present New …

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option and License Agreement to Advance Vectorized Antibodies for the treament of Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

September 18, 2025 0

VectorY Therapeutics in the NEWS September 18, 2025 – VectorY Therapeutics, a biotechnology company developing innovative …

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.

September 18, 2025 0

Lexicon Pharmaceuticals in the NEWS Yesterday, September 17, 2025, Lexicon Pharmaceuticals (LXRX) announced the presentation of …

Eli Lilly’s Oral GLP-1, Orforglipron, is Superior to Oral Semaglutide in Head-to-Head Trial

September 17, 2025 0

Eli Lilly Eli Lilly and Company (LLY) today September 17, announced positive topline results from ACHIEVE-3, Phase …

Jazz Pharmaceuticals to Treat H3 K27M-Mutant Diffuse Midline Glioma

September 16, 2025 0

Jazz Pharmaceuticals On September 9, 2025, Jazz Pharmaceuticals plc (JAZZ) announced that Modeyso™ (dordaviprone) is recommended by …

The FDA is Taking Concrete Steps to Reduce Opioid Misuse, Addiction and Overdose Strengthening Guidance on Their Appropriate Use

September 11, 2025 0

Xenon Pharmaceuticals A Company Treating Chronic Pain Xenon Pharmaceuticals (XENE) - a neuroscience-focused biopharmaceutical company dedicated …

Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes. The Stock’s Price is Soaring.

September 9, 2025 0

Alnylam Pharmaceuticals Press Release Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that …

Regeneron Pharmaceuticals Libtayo® Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-Small Cell Lung Cancer

September 9, 2025 0

Regeneron Pharmaceuticals Announcement Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a …

Alkermes: Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

September 8, 2025 0

Alkermes in the NEWS Today, Alkermes Inc., (ALKS) announced detailed positive results from the Vibrance-1 phase …

Ionis Pharmaceuticals Product Olezarsen Significantly Reduces Triglycerides and Acute Pancreatitis Events in Landmark Pivotal Studies for People with Severe Hypertriglyceridemia

September 2, 2025 0

Ionis Pharmaceuticals in the NEWS Today, Sep. 2, 2025, Ionis Pharmaceuticals (IONS) announced positive topline results …

Alnylam’s Presentation In Early September

August 28, 2025 0

Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals (ALNY) will present two investor conferences. The …

FDA New Approvals of COVID-19 Vaccines

August 28, 2025 0

Approved COVID-19 Vaccines As of late August 2025, the U.S. Food and Drug Administration (FDA) has …

BioArctic and Novartis Sign a Collaboration and License Agreement Using BrainTransporter™

August 27, 2025 0

BioArtic AB & Novartis Sign Agreement Stockholm, Sweden, August 26, 2025 – BioArctic AB (publ) (Nasdaq …

How to Bring Undervalued Stocks to Their Real Values and What About Intellia Therapeutics Stock?

August 26, 2025 0

One bad market day or more can help investors make it a good biotech market day. …

Ionis Pharmaceuticals DAWNZERA™ Granted US FDA Approval as First and Only RNA-Targeted Prophylactic Treatment for Hereditary Angioedema

August 23, 2025 0

Ionis Pharmaceuticals Ionis Pharmaceuticals (IONS) announced that the U.S. FDA has approved DAWNZERA™ (donidalorsen) for prophylaxis …